Results 101 to 110 of about 2,224 (175)

The impact of ESG performance on corporate innovation-Empirical evidence from Chinese pharmaceutical listed companies. [PDF]

PLoS One
Li L, Wang S, Chen Y.
europepmc   +1 more source

Exploring the impact of ESG controversies on private hospital performance in China. [PDF]

Medicine (Baltimore)
Yang H, Xu J.
europepmc   +1 more source

Engaging stakeholders, shaping AI ethics: Targeted engagement in corporate AI ethics statements. [PDF]

PLoS One
Ye M, Friginal E.
europepmc   +1 more source

Market competitiveness and corporate ESG performance

International Review of Economics & Finance
Taotao Zhang, Chuan Qin, Zhaoying Lu
openaire   +1 more source

Planning to fail? Credibility and financing of corporate transition plans in hard-to-abate sectors. [PDF]

iScience
Klein SMA, Polzin F, Urbach X.
europepmc   +1 more source

Capitalising (on) industrial epidemics: examining the influence of the 'Big Three' asset managers on corporate governance in key health-harming commodity industries. [PDF]

Global Health
Wood B, Slater S, Friel S, Schram A, Frank N, Sacks G.   +5 more
europepmc   +1 more source

Sustainability management control in healthcare organizations - current state and future directions. [PDF]

BMC Health Serv Res
Bauer P, Greiling D, Grüb-Martin B, Kienast L.   +3 more
europepmc   +1 more source

The nonlinear impact of ESG performance on audit pricing: Evidence from China. [PDF]

PLoS One
Li Y, Meng F.
europepmc   +1 more source

Independent companies in the tobacco supply chain: transparency and environmental social governance. [PDF]

Tob Control
Dunwoodie Stirton F, Hiscock R, Mehegan J, Gallagher AWA, Bloomfield MJ.   +4 more
europepmc   +1 more source

Air pollution and corporate labor cost stickiness: Evidence from China. [PDF]

PLoS One
Ma J.
europepmc   +1 more source